Study of Oral MRT-2359 in Selected Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to DLBCL
Related studies linked through entity extraction aliases.
Study of SGR-1505 in Mature B-Cell Neoplasms
- Status
- RECRUITING
- Phase
- PHASE1
SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
- Status
- RECRUITING
- Phase
- N/A
Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
- Status
- COMPLETED
- Phase
- PHASE1
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
- Status
- UNKNOWN
- Phase
- PHASE1
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
- Status
- SUSPENDED
- Phase
- PHASE1/PHASE2
R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study
- Status
- UNKNOWN
- Phase
- PHASE2
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- EARLY_PHASE1